RYSTIGGO
GrowthmAbBLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYSTIGGO (rozanolixizumab) is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn), reducing circulating immunoglobulin levels. It is administered subcutaneously and treats autoimmune conditions driven by pathogenic antibodies. The drug represents a novel mechanism targeting antibody recycling rather than production.
$0.006BPart D
GrowthEarly-stage growth trajectory with 186 Part D claims in 2023; commercial infrastructure expansion likely as market penetration increases.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RYSTIGGO represents an early-stage growth opportunity within a competitive but expanding FcRn blocker class; career roles center on building market share against established competitor VYVGART. Professionals joining UCB on this product will participate in market maturation, indication expansion, and establishment of the subcutaneous FcRn blocker category.
Brand Manager
Worked on RYSTIGGO at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.